Brokerages predict that DelMar Pharmaceuticals Inc (NASDAQ:DMPI) will announce earnings per share of ($0.15) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for DelMar Pharmaceuticals’ earnings. DelMar Pharmaceuticals posted earnings of ($0.13) per share in the same quarter last year, which indicates a negative year over year growth rate of 15.4%. The firm is expected to issue its next earnings report on Friday, February 9th.
On average, analysts expect that DelMar Pharmaceuticals will report full-year earnings of ($0.54) per share for the current year. For the next year, analysts forecast that the company will post earnings of ($0.69) per share. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow DelMar Pharmaceuticals.
DelMar Pharmaceuticals (NASDAQ:DMPI) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01).
In other news, CEO Saiid Zarrabian bought 60,900 shares of DelMar Pharmaceuticals stock in a transaction on Tuesday, November 14th. The shares were purchased at an average price of $0.82 per share, for a total transaction of $49,938.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
Several hedge funds have recently bought and sold shares of DMPI. Susquehanna International Group LLP purchased a new position in shares of DelMar Pharmaceuticals during the 3rd quarter worth approximately $306,000. Sabby Management LLC purchased a new position in shares of DelMar Pharmaceuticals during the 2nd quarter worth approximately $1,484,000. Finally, Franklin Resources Inc. purchased a new position in shares of DelMar Pharmaceuticals during the 2nd quarter worth approximately $2,477,000. Hedge funds and other institutional investors own 16.91% of the company’s stock.
DelMar Pharmaceuticals (NASDAQ:DMPI) traded up $0.09 on Friday, reaching $1.40. The company’s stock had a trading volume of 230,178 shares, compared to its average volume of 1,380,000. The company has a market cap of $32.32, a price-to-earnings ratio of -2.06 and a beta of 1,227.20. DelMar Pharmaceuticals has a fifty-two week low of $0.78 and a fifty-two week high of $5.39.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/20/analysts-expect-delmar-pharmaceuticals-inc-dmpi-to-post-0-15-earnings-per-share.html.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.